Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Radiol Med ; 125(9): 801-815, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32249391

RESUMEN

Hemangiomas are the most common benign tumors of the liver. These lesions are typically asymptomatic, solitary and almost always discovered incidentally, and in recent years with advances in imaging technology these lesions are being detected more frequently. Although, in majority of the cases, the imaging diagnosis of a liver hemangioma is clearly and confidently established, not all hemangiomas present with their characteristic or typical appearance on imaging. Occasionally, these lesions do present with an atypical pattern, and can be confused with other malignant lesions such as hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular-cholangiocarcinoma and angiosarcoma. In this article, we review with illustrations the diverse imaging appearances of hemangiomas on the commonly used imaging modalities, as well as provide a gamut of common and uncommonly encountered hemangioma mimickers. Knowledge of the various atypical avatars of this benign lesion is important and can help one circumvent diagnostic errors, thereby potentially avoiding unnecessary surgeries.


Asunto(s)
Carcinoma Hepatocelular/diagnóstico por imagen , Colangiocarcinoma/diagnóstico por imagen , Hemangioma/diagnóstico por imagen , Hemangiosarcoma/diagnóstico por imagen , Neoplasias Hepáticas/diagnóstico por imagen , Calcinosis/diagnóstico por imagen , Diagnóstico Diferencial , Hígado Graso/diagnóstico por imagen , Hiperplasia Nodular Focal/diagnóstico por imagen , Humanos , Imagen por Resonancia Magnética , Tomografía Computarizada por Rayos X , Ultrasonografía
2.
J Nucl Cardiol ; 27(6): 2048-2059, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-30456495

RESUMEN

BACKGROUND: Our aim was to determine if end-stage liver disease (ESLD) is associated with an attenuated response to vasodilator-stress or dobutamine-stress using 82Rb-PET MPI with blood flow quantification. METHODS AND RESULTS: Pre-liver transplant patients who had a normal dipyridamole-stress (n = 27) or dobutamine-stress (n = 26) 82Rb PET/CT MPI study with no identifiable coronary artery calcium were identified retrospectively and compared to a prospectively identified low-risk of liver disease dipyridamole-stress control group (n = 20). The dipyridamole-stress liver disease group had a lower myocardial flow reserve (MFR) (1.89 ± 0.79) than the control group (2.79 ± 0.96, P < .05). The dobutamine-stress group had a higher MFR than both other groups (3.69 ± 1.49, P < .05). A moderate negative correlation between MELD score and MFR was demonstrated for the dipyridamole-stress liver disease group (r = - 0.473, P < .05). This correlation was not observed for the dobutamine-stress liver disease group (r = - 0.253, P = .21). The liver failure group as a whole (n = 53) had a higher resting myocardial blood flow (0.97 ± 0.33 mL/min/g) than the control group (0.82 ± 0.26, P < .05). CONCLUSION: Dipyridamole demonstrates an attenuated vasodilatory response in ESLD patients compared to a non-ESLD control group related to higher resting blood flow and comparatively reduced stress blood flow. Dobutamine does not demonstrate this effect implying it may be the preferred pharmacologic MPI stress agent for ESLD patients.


Asunto(s)
Dobutamina , Enfermedad Hepática en Estado Terminal/diagnóstico por imagen , Fallo Hepático/diagnóstico por imagen , Imagen de Perfusión Miocárdica/métodos , Tomografía Computarizada por Tomografía de Emisión de Positrones/métodos , Radioisótopos de Rubidio , Vasodilatación , Adulto , Anciano , Circulación Coronaria/fisiología , Dipiridamol , Femenino , Humanos , Fallo Hepático/cirugía , Trasplante de Hígado , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Análisis de Regresión , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Vasodilatadores
3.
Abdom Radiol (NY) ; 45(3): 842-850, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31552462

RESUMEN

PURPOSE: MRI is the current imaging gold standard to diagnose adenomyosis, but access is often limited by high costs and availability. Transvaginal ultrasound provides a cost-effective, accurate and readily available alternative. The objective of our study was to determine the diagnostic accuracy of commonly described sonographic findings in predicting uterine adenomyosis. METHODS: This retrospective study evaluated 649 MRI studies performed to investigate adenomyosis with a preceding transvaginal ultrasound within 12 months between 2013 and 2018. Two blinded reviewers assessed the presence or absence of six sonographic features: bulky uterus, heterogeneous myometrium, streaky myometrium, myometrial cysts, endometrial-myometrial interface ill-definition, and echogenic linear striations. The sensitivity, specificity, positive and negative predictive values of these features were calculated individually and in combination when compared to MRI as the standard of reference. RESULTS: Adenomyosis was found in 315 (48.5%) cases on MRI. Ultrasound had a high specificity of 91.8% (95% CI 88.4 to 94.6%) but was less sensitive (36.8% (95% CI 31.5 to 42.4%)) for detecting adenomyosis. Comorbid fibroids or focal adenomyosis did not affect diagnostic accuracy. All six variables were significantly more common in patients with adenomyosis compared to those without. Individually, 'bulky uterus' and 'heterogenous myometrium' each demonstrated a mean sensitivity and specificity > 50%. The best dual combined variables were 'bulky uterus' + 'ill definition of the endometrial-myometrial interface' (sensitivity 39%, specificity 91%). The best triple combined variables were 'bulky uterus', 'heterogeneous myometrium' + 'ill definition of the endometrial-myometrial interface' (sensitivity 38%, specificity 93%). CONCLUSION: Transvaginal ultrasound is highly specific for diagnosing uterine adenomyosis, providing a cost-effective and readily available alternative to MRI.


Asunto(s)
Adenomiosis/diagnóstico por imagen , Imagen por Resonancia Magnética/métodos , Ultrasonografía/métodos , Adulto , Anciano , Femenino , Humanos , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Sensibilidad y Especificidad
4.
Diabetes ; 62(3): 711-20, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23139350

RESUMEN

Impaired skeletal muscle fatty acid oxidation has been suggested to contribute to insulin resistance and glucose intolerance. However, increasing muscle fatty acid oxidation may cause a reciprocal decrease in glucose oxidation, which might impair insulin sensitivity and glucose tolerance. We therefore investigated what effect inhibition of mitochondrial fatty acid uptake has on whole-body glucose tolerance and insulin sensitivity in obese insulin-resistant mice. C57BL/6 mice were fed a high-fat diet (60% calories from fat) for 12 weeks to develop insulin resistance. Subsequent treatment of mice for 4 weeks with the carnitine palmitoyltransferase-1 inhibitor, oxfenicine (150 mg/kg i.p. daily), resulted in improved whole-body glucose tolerance and insulin sensitivity. Exercise capacity was increased in oxfenicine-treated mice, which was accompanied by an increased respiratory exchange ratio. In the gastrocnemius muscle, oxfenicine increased pyruvate dehydrogenase activity, membrane GLUT4 content, and insulin-stimulated Akt phosphorylation. Intramyocellular levels of lipid intermediates, including ceramide, long-chain acyl CoA, and diacylglycerol, were also decreased. Our results demonstrate that inhibition of mitochondrial fatty acid uptake improves insulin sensitivity in diet-induced obese mice. This is associated with increased carbohydrate utilization and improved insulin signaling in the skeletal muscle, suggestive of an operating Randle Cycle in muscle.


Asunto(s)
Fármacos Antiobesidad/uso terapéutico , Carnitina O-Palmitoiltransferasa/antagonistas & inhibidores , Inhibidores Enzimáticos/uso terapéutico , Resistencia a la Insulina , Metabolismo de los Lípidos/efectos de los fármacos , Mitocondrias Musculares/efectos de los fármacos , Obesidad/tratamiento farmacológico , Animales , Metabolismo de los Hidratos de Carbono/efectos de los fármacos , Carnitina O-Palmitoiltransferasa/metabolismo , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Dieta Alta en Grasa/efectos adversos , Intolerancia a la Glucosa/etiología , Intolerancia a la Glucosa/prevención & control , Transportador de Glucosa de Tipo 4/metabolismo , Glicina/análogos & derivados , Glicina/uso terapéutico , Masculino , Ratones , Ratones Endogámicos C57BL , Mitocondrias Musculares/enzimología , Mitocondrias Musculares/metabolismo , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/enzimología , Músculo Esquelético/metabolismo , Obesidad/etiología , Obesidad/metabolismo , Obesidad/fisiopatología , Distribución Aleatoria , Transducción de Señal/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA